Deanna Zhang of Tudor, Pickering, Holt & Co. joined the Houston Innovators Podcast to discuss 2020's effect on the energy transition — and what that meant for startups. Photo courtesy of TPH

In 2020, the economy was hit with a double whammy of sorts — from a devastating pandemic to an unprecedented drop in oil prices — and that has meant that the energy transition is happening at a faster pace than ever.

Deeana Zhang, director of energy technology at Tudor, Pickering, Holt & Co., joined the Houston Innovators Podcast this week to discuss what she observed throughout the year as she worked closely with energy tech businesses.

"Because it was such a disruptive year, everyone — from the commercial and business side to the consumer side — has rethought how they are using and thinking about energy," she says on the show. "It was the first time that you saw such a mass disruption of energy demand, and that rolls through the entire ecosystem."

The effect touched all four corners of the industry in some way, and it forced all major energy players to be more intentional with their business strategy — especially when it comes to the role they play within the energy transition.

"The energy transition saw a huge uptick in 2020 — and there's a lot of implications of that from what pilots are getting commercialized and what companies are getting more funding," says Zhang. "All around it was hugely disruptive — but hugely beneficial I think to the energy transition."

Environmental, social and corporate governance, which has been growing in importance to investors and company leadership for several years now, also got a spur from 2020. ESG has been propelled by activism and consumer choice, Zhang says, but now investors are now forced to be more cognizant than ever.

"What's the investor responsibility to society as a whole? It's going beyond economics — what's your social and environmental responsibility? I think a lot of that expansion of responsibility is what's driving ESG," she says. "That's going to trickle down corporations and companies as they think about what is their expanded responsibility."

Zhang, who works closely with energy startups, also observed a profound effect when it came to capital and new business.

"A lot of companies say numbers go down in 2020, but the exceptions to that were companies that had a strong energy transition angle. Those companies were able to reposition themselves to ... counteract what was going on in the market in general," Zhang says. "From a capital raising standpoint, it was also really challenging. A lot of funds put a hold on investing in new companies and even some to their existing portfolio."

Investment came back toward the second half of the year, but there was a new level of caution, she says, and this is something startups saw happening across the country.

Zhang discusses more about what she saw happen last year for energy technology — as well as what that means for 2021 — on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”